SurVaxM Clinical Trials (2026): 4 Studies for Anaplastic Astrocytoma & Anaplastic Ependymoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 SurVaxM clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Anaplastic Astrocytoma & Anaplastic Ependymoma) and 323 total planned enrollment. Most recent activity: NCT04978727 (Dec 2027).
SurVaxM clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | completed | unknown | no longer available | Total |
|---|---|---|---|---|---|
| P1 | 1 | 1 | |||
| P2 | 1 | 1 | 2 | ||
| N/A | 1 | 1 |
SurVaxM clinical trials by indication
Medulloblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04978727 | — | P1 | active not recruiting | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma |
Newly Diagnosed Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05163080 | SURVIVE | P2 | unknown | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) |
Recurrent Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04013672 | — | P2 | completed | Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence |
Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04802447 | EAP | N/A | no longer available | SurVaxM Expanded Access Protocol |
SurVaxM pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SURVIVE | NCT05163080 | P2 | unknown | Newly Diagnosed Glioblastoma | 247 | — |
All SurVaxM trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04978727 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | P1 | active not recruiting | 35 | Children's Oncology Group | Jul 2022 | |
| NCT05163080 | SURVIVE | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) | P2 | unknown | 247 | MimiVax, LLC | Nov 2021 |
| NCT04013672 | Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence | P2 | completed | 41 | David Peereboom | Mar 2020 | |
| NCT04802447 | EAP | SurVaxM Expanded Access Protocol | — | no longer available | 0 | Roswell Park Cancer Institute | — |
SurVaxM clinical trials: frequently asked questions
- How many SurVaxM clinical trials are there?
- 4 SurVaxM clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is marked completed.
- Are SurVaxM clinical trials recruiting in 2026?
- No active SurVaxM trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is SurVaxM being studied for?
- SurVaxM is being studied for Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Diffuse Intrinsic Pontine Glioma, Ependymoma and 6 more. The trials are grouped by indication on this page.
- What phase is SurVaxM in?
- SurVaxM clinical trials span 2 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors SurVaxM clinical trials?
- The lead sponsor across the most SurVaxM trials is Children's Oncology Group, with 3 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming SurVaxMas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: